A New Era of QMS Regulation

The FDA’s transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR) represents one of the most significant regulatory updates affecting medical device manufacturers in decades. But despite the attention surrounding the change, many organizations are still asking a simple question:

What changed?

At its core, the QMSR transition reflects the FDA’s decision to align its quality system requirements with ISO 13485:2016, the internationally recognized standard for medical device quality management systems. Rather than maintaining a standalone regulatory framework, FDA has incorporated ISO 13485 into 21 CFR Part 820, creating a regulatory structure that better reflects global quality management practices.

Understanding the differences between the QSR and QMSR frameworks is essential for manufacturers preparing for the transition.

The Quality System Regulation (QSR)

For more than two decades, the QSR under 21 CFR Part 820 has defined FDA’s expectations for medical device quality systems. The regulation established requirements covering design controls, document controls, purchasing controls, production and process controls, corrective and preventive action (CAPA), complaint handling, and quality system records.

Although the QSR framework shares many similarities with ISO 13485, it has historically existed as a distinct regulatory structure, requiring many manufacturers to maintain parallel systems to satisfy both FDA and international regulatory requirements.

The Quality Management System Regulation (QMSR)

The QMSR restructures FDA’s device quality system regulation by incorporating ISO 13485:2016 directly into Part 820.

Under the new regulation, ISO 13485 becomes the foundation of FDA quality system requirements, although FDA maintains certain additional regulatory provisions in Part 820. Because of this, manufacturers must ensure compliance with both ISO 13485 and applicable FDA requirements.

This approach reflects FDA’s long-standing participation in international regulatory harmonization initiatives and acknowledges the widespread adoption of ISO 13485 across global medical device markets.

QMSR structural changes

While many quality principles remain familiar, several structural changes distinguish the QMSR framework from the traditional QSR.

Alignment with ISO 13485 structure

The most visible change is the shift to the ISO 13485 clause structure, which organizes quality system requirements into sections such as Quality Management System, Management Responsibility, Resource Management, Product Realization, and Measurement, Analysis, and Improvement.

This structure reflects a process-oriented quality management approach rather than the procedural structure used in the QSR.

Greater emphasis on risk-based quality management

ISO 13485 integrates risk management concepts throughout the quality management system. As a result, manufacturers must demonstrate that risk considerations are incorporated into processes such as design and development, supplier management, process validation, and post-market activities.

Although risk management has always been important in device regulation, the QMSR framework reinforces its system-wide role in quality management.

Harmonization with global regulatory expectations

By aligning with ISO 13485, the QMSR reduces the regulatory fragmentation that manufacturers previously faced when maintaining separate systems for FDA compliance and international markets.

For organizations already operating under ISO-certified quality systems, the QMSR may simplify compliance efforts by allowing a single integrated quality management system.

What did not change

Despite the structural shift toward ISO 13485, many of the core expectations of FDA inspections remain the same. Manufacturers must still demonstrate effective implementation of key quality system processes, including design controls, CAPA systems, complaint handling, nonconforming product control, process validation, supplier management, and document and record control.

These processes have long been central to FDA inspections and continue to play a critical role under the QMSR framework.

In practice, many organizations will find that the operational foundation of their quality systems remains familiar, even as the regulatory structure evolves.

The relationship between ISO 13485 and FDA requirements

One important feature of the QMSR is that ISO 13485 does not replace FDA regulatory authority. Instead, it serves as the core quality management framework within the regulatory structure.

FDA-specific provisions within Part 820 remain applicable and must be addressed by manufacturers.

This means organizations must understand how ISO requirements and FDA regulatory obligations interact, rather than if ISO certification alone ensures full regulatory compliance.

What it means for manufacturers

For many device manufacturers, the transition from QSR to QMSR is less about building new quality systems and more about aligning existing systems with the ISO-based structure.

Practical transition activities may include performing QSR-to-QMSR gap analyses, aligning quality system documentation with ISO terminology, strengthening risk management integration, updating internal audit frameworks, and preparing for ISO-aligned FDA inspections.

Organizations that approach the transition systematically will likely find that their existing quality systems already contain many of the required elements.

A step toward global regulatory consistency

Ultimately, the QMSR represents a step toward greater regulatory alignment across international markets. By adopting ISO 13485 as the foundation of its quality system regulation, FDA has signaled its commitment to a more harmonized global regulatory environment.

For manufacturers operating in multiple jurisdictions, this alignment may reduce complexity and support the development of more integrated quality management systems.

The key for organizations moving forward is not simply understanding the regulatory change—but ensuring that their quality systems remain effective, well integrated, and inspection-ready under the new framework.